No disclosed relationships extracted for LIMNyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
How LIMN has moved on past release days vs its typical ±8.7% day, and how often it closed up. Computed from daily closes — not a forecast.